Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
8.17
+0.01 (0.12%)
At close: Mar 6, 2026, 4:00 PM EST
8.02
-0.15 (-1.84%)
After-hours: Mar 6, 2026, 6:58 PM EST
Fulcrum Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 80 | 2.81 | 6.34 | 19.16 | |
| Revenue Growth (YoY) | - | 2752.05% | -55.77% | -66.91% | 117.19% | |
| Cost of Revenue | 56.1 | 63.39 | 71.8 | 76.78 | 69.7 | |
| Gross Profit | -56.1 | 16.61 | -69 | -70.44 | -50.54 | |
| Selling, General & Admin | 28.67 | 36.45 | 41.67 | 41.69 | 30.52 | |
| Operating Expenses | 28.67 | 36.45 | 41.67 | 41.69 | 30.52 | |
| Operating Income | -84.77 | -19.83 | -110.66 | -112.13 | -81.05 | |
| Interest & Investment Income | 9.89 | 12.17 | 13.33 | 2.69 | 0.21 | |
| EBT Excluding Unusual Items | -74.88 | -7.66 | -97.34 | -109.44 | -80.85 | |
| Merger & Restructuring Charges | - | -2.06 | - | -0.43 | - | |
| Pretax Income | -74.88 | -9.73 | -97.34 | -109.87 | -80.85 | |
| Net Income | -74.88 | -9.73 | -97.34 | -109.87 | -80.85 | |
| Net Income to Common | -74.88 | -9.73 | -97.34 | -109.87 | -80.85 | |
| Shares Outstanding (Basic) | 63 | 62 | 61 | 45 | 35 | |
| Shares Outstanding (Diluted) | 63 | 62 | 61 | 45 | 35 | |
| Shares Change (YoY) | 2.21% | 1.10% | 36.27% | 27.23% | 39.47% | |
| EPS (Basic) | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | |
| EPS (Diluted) | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 | |
| Free Cash Flow | -60.38 | -2.5 | -91.47 | -99.01 | -80.19 | |
| Free Cash Flow Per Share | -0.95 | -0.04 | -1.49 | -2.20 | -2.27 | |
| Gross Margin | - | 20.77% | - | - | -263.73% | |
| Operating Margin | - | -24.79% | -3945.24% | -1768.12% | -422.97% | |
| Profit Margin | - | -12.16% | -3470.05% | -1732.43% | -421.89% | |
| Free Cash Flow Margin | - | -3.12% | -3261.07% | -1561.23% | -418.47% | |
| EBITDA | -83.38 | -18.24 | -108.49 | -109.72 | -78.54 | |
| EBITDA Margin | - | -22.80% | - | - | - | |
| D&A For EBITDA | 1.39 | 1.59 | 2.17 | 2.41 | 2.52 | |
| EBIT | -84.77 | -19.83 | -110.66 | -112.13 | -81.05 | |
| EBIT Margin | - | -24.79% | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.